The October 7, 2023, Attack on Israel Indicates a Change in Trauma Patterns of Terror Victims, due to the Use of Thermobaric Weapons.

Introduction: The terror attack on October 7, 2023, in southern Israel resulted in approximately 1,200 civilians and security personnel killed. Of the civilians murdered, approximately 200 men, women, and children were murdered inside their homes, while the remaining casualties were murdered in an open field at a music festival, in their cars, or in the streets of local cities.

Materials And Methods: Currently, official data have not yet been published regarding the types of injuries suffered by Israeli civilians during the terror attack.

The Challenges of Forensic Medicine in Victim Identification in the Wake of the October 7th (2023) Mass Casualty Event.

Background: The massive terrorist attack on a mixed population of civilians, soldiers, and foreigners on October 7, 2023, resulted in 1200 casualties and led to many major personal identification issues. At the Israel National Center for Forensic Medicine (INCFM), addressing the mass casualty incidents required precision that included technical, ethical, and humanitarian dimensions. Many obstacles arose that were attributable to the vast number and diversity of victims and the heavy workload in the setting of a small forensic team.

Mass killing during terror attack at the Israel-Gaza border and the role of the Ministry of Health in identification of human remains and their release.

More than 1200 civilians and military were killed in cities and villages by the Hamas attack on October 7th, 2023. The bodies and body-parts had to be identified and released for burial. This report outlines the challenges and mode of operation of the massive disaster victim identification (DVI) efforts.

End-to-End Semi-automated Mid-scale Protein Screening Platform for Drug Discovery Research.

The drug discovery landscape is ever-evolving and constantly demands revolutionary technology advancements in protein expression and production laboratories. We have built a higher-throughput mid-scale semi-automated protein expression and screening platform to accelerate drug discovery research. The workflow described here enables comprehensive expression and purification screening assessment of challenging or difficult-to-express recombinant proteins in a fast and efficient manner by delivering small but sufficient amounts of high-quality proteins.